ID: ALA5196520

Max Phase: Preclinical

Molecular Formula: C31H36N2O4

Molecular Weight: 500.64

Representations

Canonical SMILES:  CCC(CC)O[C@@H]1C=C(C(=O)O)C[C@H](NCc2ccc(-c3ccc4ccccc4c3)cc2)[C@H]1NC(C)=O

Standard InChI:  InChI=1S/C31H36N2O4/c1-4-27(5-2)37-29-18-26(31(35)36)17-28(30(29)33-20(3)34)32-19-21-10-12-23(13-11-21)25-15-14-22-8-6-7-9-24(22)16-25/h6-16,18,27-30,32H,4-5,17,19H2,1-3H3,(H,33,34)(H,35,36)/t28-,29+,30+/m0/s1

Standard InChI Key:  GTZBMWOKSAEHFN-FRXPANAUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 500.64

Molecular Weight (Monoisotopic): 500.2675

AlogP: 5.46

#Rotatable Bonds: 10

Polar Surface Area: 87.66

Molecular Species: ZWITTERION

HBA: 4

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.21

CX Basic pKa: 8.80

CX LogP: 2.75

CX LogD: 2.74

Aromatic Rings: 3

Heavy Atoms: 37

QED Weighted: 0.34

Np Likeness Score: 0.35

References

1. Ju H, Murugan NA, Hou L, Li P, Guizzo L, Zhang Y, Bertagnin C, Kong X, Kang D, Jia R, Ma X, Du R, Poongavanam V, Loregian A, Huang B, Liu X, Zhan P..  (2021)  Identification of C5-NH₂ Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,  64  (24.0): [PMID:34735766] [10.1021/acs.jmedchem.1c01366]

Source

Source(1):

• Scientific Literature